When the Sept. 19 Oncologic Drugs Advisory Committee (ODAC) review of Pfizer Inc.'s Sutent (sunitinib) was announced for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy, it raised a red flag.
The US FDA's decision to take the application to committee was surprising – Sutent has an established history in RCC, even approved as first-line therapy – and worrisome – supplemental
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?